Expert Review of Pharmacoeconomics and Outcomes Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece
CONCLUSION: Lorlatinib provides substantial clinical benefit and appears to be a cost - effective treatment option compared to 1st and 2nd generation TKIs for previously untreated patients with ALK+ aNCSLC in Greece.PMID:37997764 | DOI:10.1080/14737167.2023.2288249 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 24, 2023 Category: Health Management Authors: George Gourzoulidis Oresteia Zisimopoulou Andrianos Liavas Charalampos Tzanetakos Source Type: research

A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia
CONCLUSION: For Chinese payers, zanubrutinib exhibited superior cost-effectiveness compared to ibrutinib. Zanubrutinib proved to be a more affordable option for US payers when considering the payment threshold.PMID:37999452 | DOI:10.1080/14737167.2023.2288683 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 24, 2023 Category: Health Management Authors: Rongqi Li Chenxiang Wang Zhongjiang Ye Yizhang Chen Jingyao Xu Chuang Chen Jianhui Yang Jing Fu Tao Zhou Ziye Zhou Xiuhua Zhang Source Type: research

Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab and benralizumab added to the standard of care in adults with severe asthma in Colombia
CONCLUSIONS: Dupilumab 200 mg was strongly dominant versus omalizumab 450 mg and600 mg, mepolizumab 100 mg and benralizumab 30 mg; however,cost-effectiveness was not demonstrated versus omalizumab 300 mg.These findings might aid in the selection of a biologic to treatsevere type 2 asthma.PMID:37994432 | DOI:10.1080/14737167.2023.2282668 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 23, 2023 Category: Health Management Authors: Abraham Ali Elizabeth Garc ía Carlos A Torres-Duque Diana Rey Laura Botero Stid Saenz Maria Paula Avila Elizabeth Mazo Sergio Londo ño Source Type: research

The economic impact of Pharmacist intervention during pandemics
Expert Rev Pharmacoecon Outcomes Res. 2023 Nov 22. doi: 10.1080/14737167.2023.2287487. Online ahead of print.NO ABSTRACTPMID:37993404 | DOI:10.1080/14737167.2023.2287487 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 22, 2023 Category: Health Management Authors: Ahmad Z Al Meslamani Anan S Jarab Source Type: research